Dated: January 15, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97–1482 Filed 1–21–97; 8:45 am]

BILLING CODE 4160–01–F

National Institutes of Health

National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for Partnering, Informatics and Technology Development

AGENCY: National Cancer Institute, National Institutes of Health, PHS, DHHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (DHHS) seeks a company that can collaboratively pursue development of an expert, information based system of technology development and transfer. In particular, the Office of Technology Development (''OTD''), National Cancer Institute seeks to co-develop a system for modeling current OTD processes. The system will be tested using both the selected collaborator's processes and outcomes and real-time OTD experiences.

ADDRESSES: Questions about this opportunity may be addressed to William Cotreau, J.D., or Jeremy A. Cubert, M.S., J.D., Office of Technology Development, NCI, 6120 Executive Blvd., MSC 7182, Bethesda, MD 20892–7182, Phone: (301) 496–0477, Facsimile: (301) 402–2117. from whom further information may be obtained.

DATES: In view of the important priority of developing a technology informatics system, interested parties should notify this office in writing no later than March 10, 1997. Respondents will then be provided an additional 30 days for the filing of formal proposals.

SUPPLEMENTARY INFORMATION:

''Cooperative Research and Development Agreement'' or ''CRADA'' means the anticipated joint agreement to be entered into by NCI pursuant to the Federal Technology Transfer Act of 1986 and amendments (including 104 P.L. 133) and Executive Order 12591 of October 10, 1987 to collaborate on the specific research project described below.

The Office of Technology Development (OTD) serves as the Institute focal point for the implementation of the Federal Technology Transfer Act of 1986. The OTD provides advice, guidance and assistance to Institute staff on such things as: the development and management of intellectual property; registration and management of patents; terms and negotiation of licensing and research and development agreements; management and administration of royalties; transfer of research material; interpretation of laws, policies, rules and regulations especially related to the implementation of the Federal Technology Transfer Act; and other related matters.

The Government is seeking a partner with which, in accordance with the requirements of the regulations governing the transfer of technology in which the Government has taken an active role in developing (37 CFR 404.8), can co-develop a system for modeling technology development processes using information technologies. The National Cancer Institute will provide access to its knowledge and skill base, information regarding current processes and a test bed of technologies not subject to confidentiality obligations. The selected Collaborator will provide expertise in Technology Development, current processes and market awareness.

The expected duration of the CRADA will be two (2) to five (5) years.

The role of the National Cancer Institute, includes the following:

(1) demonstrate current technology development processes related to transactional research agreements.

(2) proof model/equations for logical structure.

(3) provide/input historical NCI–OTD data that are not subject to any confidentiality obligation(s) or where necessary ensure appropriate provisions of confidentiality are applied.

(4) input collaborator historical data.

(5) review model for logical structure.

(6) provide current examples that are not subject to confidentiality obligation(s) or where necessary ensure appropriate provisions of confidentiality are applied in order to further test model.

The role of the collaborator company, includes the following:

(1) program model of NCI current processes related to transactional research agreements.

(2) provide input and feedback regarding NCI processes related to transactional research agreements.

(3) amend model based on feedback from NCI and Collaborator.

(4) provide sufficient information about Collaborator technology development processes to elucidate and improve model.

(5) revise model as necessary.

(6) jointly test model using current NCI technology that is not subject to confidentiality obligation(s) as examples or where necessary ensure appropriate provisions of confidentiality are applied.

(7) develop commercial version of technology development information system.

(8) provide resources as necessary.

Dated: January 8, 1997.

Thomas D. Mays,

Director, Office of Technology Development, OIM, NCI.

[FR Doc. 97–1533 Filed 1–21–97; 8:45 am]

BILLING CODE 4140–10–M

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development.

ADDRESSES: Licensing information and a copy of the U.S. patent application referenced below may be obtained by contacting George H. Keller, Ph.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804 (telephone 301/496–7735 ext. 246; fax 301/402–0220). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

Hepatitis A Virus Receptor and Methods of Use

G Kaplan, SM Feinstone (FDA)

Serial No. 08/287,001 filed 05 Aug 94

This invention describes the discovery and isolation of HAVcr–1, a simian cellular receptor for the hepatitis A virus (HAV). Cells nonpermissive to HAV infection transfected with HAVcr–1 cDNA, a novel cell surface mucin-like glycoprotein, gain susceptibility to HAV infection. The invention claims nucleic acids encoding cellular receptors to HAV which hybridize with HAVcr–1 probes. The invention also claims peptides encoded by the above-mentioned HAV receptor nucleic acid.

Potential areas of application include use of HAVcr–1 receptors for diagnostics; use of HAVcr–1 receptors for treatment of patients infected with HAV; development of compounds capable of interacting with HAVcr–1 receptors which could inhibit HAV